The IC50 of anti-Pfs25 antibody in membrane-feeding assay varies among species

Lediya Cheru; Yimin Wu; Ababacar Diouf; Samuel E. Moretz; Olga V. Muratova; Guanhong Song; Michael P. Fay; Louis H. Miller; Carole A. Long; Kazutoyo Miura

doi:10.1016/j.vaccine.2010.04.036

The IC₅₀ of anti-Pfs25 antibody in membrane-feeding assay varies among species

Lediya Cheru
, Yimin Wu
, Ababacar Diouf
, Samuel E. Moretz
, Olga V. Muratova
, Guanhong Song
, Michael P. Fay
, Louis H. Miller
, Carole A. Long
, Kazutoyo Miura

Research output: Contribution to journal › Article › peer-review

Abstract

Plasmodium falciparum surface protein 25 (Pfs25) is a candidate for transmission-blocking vaccines (TBVs). Anti-Pfs25 antibodies block the development of oocysts in membrane-feeding assays and we have shown the activity correlates with antibody titer. In this study, we purified Pfs25-specific IgGs to convert antibody titer to μg/mL and determined the amount of antibody required to inhibit 50% of oocyst development (IC₅₀). The IC₅₀ were, 15.9, 4.2, 41.2, and 85.6 μg/mL for mouse, rabbit, monkey and human, respectively, and the differences among species were significant. Anti-Pfs25 sera from rabbit, monkey and human showed different patterns of competition against 6 mouse monoclonal antibodies, and the avidity of antibodies among four species were also different. These data suggests that information obtained from animal studies which assess efficacy of TBV candidates may be difficult to translate to human immunization.

Original language	English (US)
Pages (from-to)	4423-4429
Number of pages	7
Journal	Vaccine
Volume	28
Issue number	27
DOIs	https://doi.org/10.1016/j.vaccine.2010.04.036
State	Published - Jun 17 2010
Externally published	Yes

Keywords

Plasmodium falciparum
Transmission-blocking vaccine
Vaccine development

ASJC Scopus subject areas

Molecular Medicine
General Immunology and Microbiology
General Veterinary
Public Health, Environmental and Occupational Health
Infectious Diseases

Access to Document

10.1016/j.vaccine.2010.04.036

Cite this

@article{477f7b80a6464314beff1f1e06e7a2a4,

title = "The IC50 of anti-Pfs25 antibody in membrane-feeding assay varies among species",

abstract = "Plasmodium falciparum surface protein 25 (Pfs25) is a candidate for transmission-blocking vaccines (TBVs). Anti-Pfs25 antibodies block the development of oocysts in membrane-feeding assays and we have shown the activity correlates with antibody titer. In this study, we purified Pfs25-specific IgGs to convert antibody titer to μg/mL and determined the amount of antibody required to inhibit 50\% of oocyst development (IC50). The IC50 were, 15.9, 4.2, 41.2, and 85.6 μg/mL for mouse, rabbit, monkey and human, respectively, and the differences among species were significant. Anti-Pfs25 sera from rabbit, monkey and human showed different patterns of competition against 6 mouse monoclonal antibodies, and the avidity of antibodies among four species were also different. These data suggests that information obtained from animal studies which assess efficacy of TBV candidates may be difficult to translate to human immunization.",

keywords = "Plasmodium falciparum, Transmission-blocking vaccine, Vaccine development",

author = "Lediya Cheru and Yimin Wu and Ababacar Diouf and Moretz, \{Samuel E.\} and Muratova, \{Olga V.\} and Guanhong Song and Fay, \{Michael P.\} and Miller, \{Louis H.\} and Long, \{Carole A.\} and Kazutoyo Miura",

year = "2010",

month = jun,

day = "17",

doi = "10.1016/j.vaccine.2010.04.036",

language = "English (US)",

volume = "28",

pages = "4423--4429",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier Ltd",

number = "27",

}

TY - JOUR

T1 - The IC50 of anti-Pfs25 antibody in membrane-feeding assay varies among species

AU - Cheru, Lediya

AU - Wu, Yimin

AU - Diouf, Ababacar

AU - Moretz, Samuel E.

AU - Muratova, Olga V.

AU - Song, Guanhong

AU - Fay, Michael P.

AU - Miller, Louis H.

AU - Long, Carole A.

AU - Miura, Kazutoyo

PY - 2010/6/17

Y1 - 2010/6/17

N2 - Plasmodium falciparum surface protein 25 (Pfs25) is a candidate for transmission-blocking vaccines (TBVs). Anti-Pfs25 antibodies block the development of oocysts in membrane-feeding assays and we have shown the activity correlates with antibody titer. In this study, we purified Pfs25-specific IgGs to convert antibody titer to μg/mL and determined the amount of antibody required to inhibit 50% of oocyst development (IC50). The IC50 were, 15.9, 4.2, 41.2, and 85.6 μg/mL for mouse, rabbit, monkey and human, respectively, and the differences among species were significant. Anti-Pfs25 sera from rabbit, monkey and human showed different patterns of competition against 6 mouse monoclonal antibodies, and the avidity of antibodies among four species were also different. These data suggests that information obtained from animal studies which assess efficacy of TBV candidates may be difficult to translate to human immunization.

AB - Plasmodium falciparum surface protein 25 (Pfs25) is a candidate for transmission-blocking vaccines (TBVs). Anti-Pfs25 antibodies block the development of oocysts in membrane-feeding assays and we have shown the activity correlates with antibody titer. In this study, we purified Pfs25-specific IgGs to convert antibody titer to μg/mL and determined the amount of antibody required to inhibit 50% of oocyst development (IC50). The IC50 were, 15.9, 4.2, 41.2, and 85.6 μg/mL for mouse, rabbit, monkey and human, respectively, and the differences among species were significant. Anti-Pfs25 sera from rabbit, monkey and human showed different patterns of competition against 6 mouse monoclonal antibodies, and the avidity of antibodies among four species were also different. These data suggests that information obtained from animal studies which assess efficacy of TBV candidates may be difficult to translate to human immunization.

KW - Plasmodium falciparum

KW - Transmission-blocking vaccine

KW - Vaccine development

UR - https://www.scopus.com/pages/publications/77952741850

UR - https://www.scopus.com/pages/publications/77952741850#tab=citedBy

U2 - 10.1016/j.vaccine.2010.04.036

DO - 10.1016/j.vaccine.2010.04.036

M3 - Article

C2 - 20434549

AN - SCOPUS:77952741850

SN - 0264-410X

VL - 28

SP - 4423

EP - 4429

JO - Vaccine

JF - Vaccine

IS - 27

ER -